Early detection of chemotherapy-induced cardiotoxicity in lymphoma patients: RT-3DE/2D-STI and predictive role of LAEFa/LASr

淋巴瘤患者化疗诱发心脏毒性的早期检测:RT-3DE/2D-STI 和 LAEFa/LASr 的预测作用

阅读:1

Abstract

OBJECTIVE: To evaluate the utility of real-time three-dimensional echocardiography (RT-3DE) and two-dimensional speckle tracking imaging (2D-STI) for early detection of chemotherapy-induced cardiotoxicity in lymphoma patients, and to identify independent predictors of cardiotoxicity using these imaging parameters. METHODS: We conducted a single-center retrospective cohort study at The First People's Hospital of Changde City, enrolling 110 lymphoma patients who received anthracycline-based chemotherapy between January 2020 and January 2024. Echocardiographic assessments, including RT-3DE and 2D-STI, were performed before chemotherapy and within 72 hours after the 3rd and 6th cycles. Cardiotoxicity was defined as a ≥ 10% reduction in left ventricular ejection fraction (LVEF) or an LVEF < 50%. RESULTS: Baseline clinical characteristics showed significant differences in gender and hypertension between the cardiotoxic and non-cardiotoxic groups (both P < 0.05). RT-3DE revealed time-dependent changes, with LAEFa higher and LAEFa/LAEFt lower in the cardiotoxic group at 3 and 6 weeks post-chemotherapy, respectively (all P < 0.05). 2D-STI showed significant differences in LASct and LASr at 3 and 6 weeks (all P > 0.05). GEE analysis indicated that changes in LAEFa, LAEFp, LAEFt, LASr, LASct, and LVEF were driven by the time × group interaction effect (all P < 0.05). CONCLUSION: RT-3DE and 2D-STI are sensitive for early detection of anthracycline-induced cardiotoxicity in lymphoma patients. LA functional indices (LAEFa, LAEFp, LAEFt) and LA strain indices (LASr, LASct) may detect cardiotoxicity earlier than LVEF, suggesting their potential role in optimizing cardio-oncology monitoring strategies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。